Role of β2-microglobulin and lactoferrin in differential diagnosis of uremic pseudoperitonitis and peritonitis in patients with renal replacement therapy (program hemodialysis)

Abstract

The significance of the serum concentrations of β2-microglobulin and lactoferrin of the patients on a renal replacement therapy (program hemodialysis) for differential diagnosis of uremic pseudoperitonitis and peritonitis is considered. The study included 56 patients with a suspected peritonitis, admitted urgently to the hospital, who received renal replacement therapy (programmed hemodialysis) in the history. The control group included 50 outpatients on a programmed hemodialysis. The study did not include patients with suspected peritonitis who did not receive programmed hemodialysis in the history. Serum concentrations of β2-microglobulin and lactoferrin were determined in the test groups. Serum β2-microglobulin concentration was found to be statistically higher than the normal in all the patients receiving a history of program hemodialysis procedures. The highest statistically significant concentration of β2-microglobulin was detected in patients with the suspected uremic pseudoperitonitis, both compared to the control group and the group of the patients with diagnosed peritonitis. The highest statistically significant concentration of lactoferrin was detected in patients with the suspected peritonitis receiving a history of program hemodialysis procedures, which is significantly higher both compared to the control group and the patients with a suspected uremic pseudoperitonitis. In the control group of outpatient patients receiving program hemodialysis procedures, no statistically significant differences in serum concentrations of β2-microglobulin and lactoferrin were detected. A statistically significant increase in the concentration of β2-microglobulin was found in uremic pseudoperitonitis, and lactoferrin in peritonitis. The obtained data do not exclude the possibility of using β2-microglobulin to diagnose the uremic pseudoperitonitis, and lactoferrin with a high probability makes it possible to establish the fact of peritonitis.

Keywords

renal replacement therapy / lactoferrin / peritonitis / programmed hemodialysis / uremic pseudoperitonitis / β2-microglobulin / hyperasotemia / laparoscopy

References

[1] Smirnov AV, Shilov VA, Dobronravov VF. National recommendations. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Nephrology. 2012;16(1):1–4. (In Russ.).

[2] Смирнов А.В., Шилов Е.М., Добронравов В.А. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению // Нефрология. 2012. Т. 16, № 1. С. 1–4.

[3] Tomilina NA, Andrusev AM, Peregudova NG, et al. Replacement therapy of end-stage chronic renal failure in the Russian Federation in 2010–2015. Report on the data of the All-Russian Register of Renal Replacement Therapy of the Russian Dialysis Society. Nephrology and Dialysis. 2018;19(4):1–95. (In Russ.). DOI: 10.28996/1680-4422-2017-4suppl-1-95

[4] Томилина Н.А., Андрусев А.М., Перегудова Н.Г., и др. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 2010–2015 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества // Нефрология и диализ. 2018. Т. 19, № 4. С. 1–95. DOI: 10.28996/1680-4422-2017-4suppl-1-95

[5] Kryukov EV, Potekhin NP, Chaplyuk AL, et. al. Expert approaches to chronic kidney disease. Military Medical Journal. 2016;337(10): 13–18. (In Russ.).

[6] Крюков Е.В., Потехин Н.П., Чаплюк А.Л., и др. Экспертные подходы при хронической болезни почек // Военно-медицинский журнал. 2016. Т. 337, № 10. С. 13–18.

[7] Bikbov BT, Tomilina NA. Composition of patients and indicators of the quality of treatment on replacement therapy for end-stage chronic renal failure in the Russian Federation in 1998–2013. Report on the data of the register of renal replacement therapy of the Russian Dialysis Society. Nephrology and Dialysis. 2016;18(2):123–127. (In Russ.).

[8] Бикбов Б.Т., Томилина Н.А. Состав больных и показатели качества лечения на заместительной терапии терминальной хронической почечной недостаточности в Российской Федерации в 1998–2013 гг. Отчет по данным регистра заместительной почечной терапии Российского диализного общества // Нефрология и диализ. 2016. Т. 18, № 2. С. 123–127.

[9] Smirnov AV, Dobronravov VA, Kayukov IG, et.al. Chronic kidney disease: Further development of the concept and classification. Nephrology. 2007;11(4):7–15. (In Russ.).

[10] Смирнов А.В., Добронравов В.А., Каюков И.Г., и др. Хроническая болезнь почек: дальнейшее развитие концепции и классификации // Нефрология. 2007. Т. 11, № 4. С. 7–15.

[11] Eilers H, Liu КD, Gruber А, Niemann U. Chronic kidney disease: implications for the perioperative period. Minerva Anestesiol. 2010;76(9):725–736.

[12] Eilers H., Liu К.D., Gruber А., Niemann U. Chronic kidney disease: implications for the perioperative period // Minerva Anestesiol. 2010. Vol. 76, No. 9. P. 725–736.

[13] Malkov IS, Shaimardanov RSh, Zainutdinov AM. Methodological aspects of laparoscopic sanation in case of diffuse peritonitis. West Surgery. 2003;162(2):28–31. (In Russ.).

[14] Малков И.С., Шаймарданов Р.Ш., Зайнутдинов А.М. Методологические аспекты лапароскопической санации при разлитом перитоните // Вестник хирургии. 2003. Т. 162, № 2. С. 28–31.

[15] Magnuson TH, Bender JS. Cholecystectomy in the peritoneal dialysis patient. Unique advantages to the laparoscopic approach. Surg Endosc Aug. 1995;9(8):908–909. DOI: 10.1007/BF00768890

[16] Magnuson T.H., Bender J.S. Cholecystectomy in the peritoneal dialysis patient. Unique advantages to the laparoscopic approach // Surg Endosc Aug. 1995. Vol. 9, No. 8. P. 908–909. DOI: 10.1007/BF00768890

[17] Ryabov SI. The present-day approaches to hemodialysis treatment of patient with chronic renal failure. Nephrology. 1999;3(1): 8–13. (In Russ.). DOI: 10.24884/1561-6274-1999-3-1-8-13

[18] Рябов С.И. Современные подходы к лечению гемодиализом больных с хронической почечной недостаточностью // Нефрология. 1999. Т. 3, № 1. С. 8–13. DOI: 10.24884/1561-6274-1999-3-1-8-13

[19] Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. National Library of Medicine. 2017;389(10075):1238–1252. DOI: 10.1016/S0140-6736(16)32064-5

[20] Webster A.C., Nagler E.V., Morton R.L., Masson P. Chronic Kidney Disease // National Library of Medicine. 2017. Vol. 389, No. 10075. P. 1238–1252. DOI: 10.1016/S0140-6736(16)32064-5

[21] Vatazin AV, Losev GYu, Filizhanko VN, et al. Application of minimally invasive surgical interventions in patients with terminal chronic renal failure receiving peritoneal dialysis. Almanac of Clinical Medicine. 2005;8(4):18–25. (In Russ.).

[22] Ватазин А.В, Лосев Г.Ю., Филижанко В.Н., и др. Применение малоинвазивных хирургических вмешательств у больных терминальной ХПН, получающих перитональный диализ // Альманах клинической медицины. 2005. № 8–4. С. 18–25.

[23] Vatazin AV, Filizhanko VN, Losev GYu, et al. Laparoscopic operations in patients with terminal chronic renal failure receiving peritoneal dialysis. Almanac of Clinical Medicine. 2007;16:46–51. (In Russ.).

[24] Ватазин А.В., Филижанко В.Н., Лосев Г.Ю., и др. Лапароскопические операции у больных терминальной ХПН получающих перитонеальный диализ // Альманах клинической медицины. 2007. Т. 16. С. 46–51.

[25] Bikbov BT, Tomilina NA. Substitution therapy for patients with chronic renal failure in the Russian Federation in 1998–2011. Nephrology and Dialysis. 2014;16(1):13–29. (In Russ.).

[26] Бикбов Б.Т., Томилина Н.А. Заместительная терапия больных с хронической почечной недостаточностью в Российской Федерации в 1998–2011 гг. // Нефрология и диализ. 2014. Т. 16, № 1. С. 13–29.

[27] Smirnov AV, Dobronravov VA, Kayukov IG, et al. Chronic kidney disease: Further development of the concept and classification. Nephrology. 2007;11(4):7–15. (In Russ.). DOI: 10.24884/1561-6274-2007-11-4-7-17

[28] Смирнов А.В., Добронравов В.А., Каюков И.Г., и др. Хроническая болезнь почек: дальнейшее развитие концепции и классификации // Нефрология. 2007. Т. 11, № 4. С. 7–15. DOI: 10.24884/1561-6274-2007-11-4-7-17

[29] Abramova EE, Koroleva IЕ, Tov NL, et al. Death risk factors in patients on hemodialysis. Journal of Siberian Medical Sciences. 2015;6:15. (In Russ.).

[30] Абрамова Е.Э., Королева И.Е., Тов Н.Л., и др. Факторы риска летальных исходов у больных на гемодиализе // Journal of Siberian Medical Sciences. 2015. № 6. С. 15.

[31] Zemchenkov AYu, Tomilina NA. “K/DOQI” refers to the origins of chronic renal failure (about the new K/DOQI section on the diagnosis, classification and assessment of the severity of chronic kidney disease. Nephrology and dialysis. 2004;(3):204–220. (In Russ.).

[32] Земченков А.Ю., Томилина Н.А. «К/ДОКИ» обращается к истокам хронической почечной недостаточности (о новом разделе K/DOQI по диагностике, классификации и оценке тяжести хронических заболеваний почек // Нефрология и диализ. 2004. № 3. С. 204–269.

[33] Kolina IB, Stavrovskaya EV, Shilov EM. Dyslipidemia and chronic progressive kidney disease. Ter Arch. 2004;76(9):75–78. (In Russ.).

[34] Колина И.Б., Ставровская Е.В., Шилов Е.М. Дислипидемия и хронические прогрессирующие заболевания почек // Терапевтический архив. 2004. Т. 76, № 9. С. 75–78.

[35] Levey AS, Coresh J, Balk E. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–147. DOI: 10.7326/0003-4819-139-2-200307150-00013

[36] Levey A.S., Coresh J., Balk E. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification // Ann Intern Med. 2003. Vol. 139, No. 2. P. 137–147. DOI: 10.7326/0003-4819-139-2-200307150-00013

[37] Kamiya T, Hirako M, Misu N. Impaired gastric motility and its relationship to gastrointestinal symptoms in patients with chronic renal failure. J Gastroenterol. 2005;40(12):1116–1122. DOI: 10.1007/s00535-005-1709-6

[38] Kamiya T., Hirako M., Misu N. Impaired gastric motility and its relationship to gastrointestinal symptoms in patients with chronic renal failure // J Gastroenterol. 2005. Vol. 40, No. 12. P. 1116–1122. DOI: 10.1007/s00535-005-1709-6

[39] Matsuo N, Yokoyama K, Maruyama Y, et.al. Clinical impact of a combined therapy of peritoneal dialysis and hemodialysis. Clin Nephrol. 2010;74(3):209–216. DOI: 10.5414/cnp74209

[40] Matsuo N., Yokoyama K., Maruyama Y., et al. Clinical impact of a combined therapy of peritoneal dialysis and hemodialysis // Clin Nephrol. 2010. Vol. 74, No. 3. P. 209–216. DOI: 10.5414/cnp74209

[41] Nazarenko GI, Kishkun AA. Clinical assessment of laboratory research results. Moscow: Medicine; 2000. 544 p. (In Russ.).

[42] Назаренко Г.И., Кишкун А.А. Клиническая оценка результатов лабораторных исследований. Москва: Медицина, 2000. 544 с.

[43] Savelyev VS, Gelfand BR, Filimonov MI. Peritonitis. Moscow: Litterra; 2006. 208 p. (In Russ.).

[44] Савельев В.С., Гельфанд Б.Р., Филимонов М.И. Перитонит. Москва: Литтерра, 2006. 208 с.

[45] Deegens J, Wetzels J. Fractional excretion of high- and low-molecular weight proteins and outcome in primary focal segmental glomerulosclerosis. Clin Nephrol. 2007;68(4):201–208. DOI: 10.5414/cnp68201

[46] Deegens J., Wetzels J. Fractional excretion of high- and low-molecular weight proteins and outcome in primary focal segmental glomerulosclerosis // Clin Nephrol. 2007. Vol. 68, No. 4. P. 201–208. DOI: 10.5414/cnp68201

[47] Jaques DA, Davenport A. Serum β2-microglobulin as a predictor of residual kidney function in peritoneal dialysis patients. J Nephrol. 2021;34(2):473–481. DOI: 10.1007/s40620-020-00906-x

[48] Jaques D.A., Davenport A. Serum β2-microglobulin as a predictor of residual kidney function in peritoneal dialysis patients // J Nephrol. 2021. Vol. 34, No. 2. P. 473–481. DOI: 10.1007/s40620-020-00906-x

[49] Lutseva OA, Zurnadzhiantc VA, Kchibekov EA, et al. Possibilities of serum indicator enzymes in the differential diagnosis of atypical forms of acute appendicitis. Bulletin of Surgical Ggastroenterology. 2018;(1):54–55. (In Russ.).

[50] Луцева О.А., Зурнаджьянц В.А., Кчибеков Э.А., и др. Возможности сывороточных индикаторных ферментов в диффренциальной диагностике атипичных форм острого аппендицита // Вестник хирургической гастроэнтерологии. 2018. № 1. С. 54–55.

[51] Coca S, Parikh C. Urinary Biomarkers for Acute Kidney Injury: Perspectiveson Translation. Clin J Am Soc Nephrol. 2008;3(2): 481–490. DOI: 10.2215/cjn.03520807

[52] Coca S., Parikh C. Urinary Biomarkers for Acute Kidney Injury: Perspectiveson Translation // Clin J Am Soc Nephrol. 2008. Vol. 3, No. 2. P. 481–490. DOI: 10.2215/cjn.03520807

RIGHTS & PERMISSIONS

Zurnadzh’yantс V.A., Kchibekov E.A., Gasanov K.G.